Current guidelines recommend clinical breast examinations beginning at ages 30-35 years and suggest mammographic screening on an individual basis, whereas clinical prostate cancer screening, particularly for BRCA2 carriers, is recommended from ages 40 to 45 years (38–40). The gene discussed is BRCA2; the disease is prostate carcinoma.